At present, several ICIs targeting PDCD1(PD-1), CD274(PD-L1) and CTLA4 have been approved for the clinical treatment of various solid tumors, including MSI-H/dMMR CRC (4, 6, 7). This evidence concerns the gene PDCD1 and colorectal carcinoma.